Crinetics Pharmaceuticals (CRNX) to Announce Earnings on Tuesday

Key Points

• Crinetics Pharmaceuticals is expected to report Q2 2026 results after Tuesday’s market close, August 4. Analysts forecast a loss of $1.23 per share and revenue of approximately $14.84 million.
• The company missed consensus EPS estimates in the prior quarter but significantly exceeded revenue expectations, reporting $10.73 million in revenue—up 2,873.4% year over year. Shares recently traded near a one-year high at $83.97.
• Analyst sentiment remains cautious, with an overall “Hold” rating and an average price target of $81, while several firms recently downgraded the stock. Institutional investors own 98.51% of shares, and two directors recently sold stock under pre-arranged trading plans.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) is expected to be posting its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Crinetics Pharmaceuticals to announce earnings of ($1.23) per share and revenue of $14.8420 million for the quarter. Parties can check the company's upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.23) EPS for the quarter, missing analysts' consensus estimates of ($1.22) by ($0.01). Crinetics Pharmaceuticals had a negative net margin of 2,747.18% and a negative return on equity of 43.96%. The firm had revenue of $10.73 million during the quarter, compared to analyst estimates of $8.51 million. During the same quarter in the prior year, the business earned ($1.04) EPS. The business's revenue was up 2873.4% compared to the same quarter last year. On average, analysts expect Crinetics Pharmaceuticals to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Crinetics Pharmaceuticals Trading Up 0.1%

Shares of CRNX traded up $0.12 during midday trading on Tuesday, reaching $83.97. The stock had a trading volume of 394,315 shares, compared to its average volume of 2,291,273. The firm has a market cap of $8.85 billion, a PE ratio of -16.37 and a beta of 0.23. The firm has a 50 day simple moving average of $50.36 and a 200-day simple moving average of $45.34. Crinetics Pharmaceuticals has a one year low of $25.83 and a one year high of $84.00.

Wall Street Analysts Forecast Growth

CRNX has been the subject of several recent analyst reports. Jefferies Financial Group downgraded shares of Crinetics Pharmaceuticals from a "buy" rating to a "hold" rating and raised their target price for the company from $55.00 to $85.00 in a research note on Tuesday, July 7th. UBS Group reiterated a "neutral" rating and issued a $85.00 price target (up from $55.00) on shares of Crinetics Pharmaceuticals in a research note on Tuesday. HC Wainwright lowered shares of Crinetics Pharmaceuticals from a "buy" rating to a "hold" rating and boosted their target price for the company from $81.00 to $85.00 in a report on Tuesday, July 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Crinetics Pharmaceuticals in a research note on Friday, July 17th. Finally, Lifesci Capital cut Crinetics Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $81.00.

Insider Activity at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, Director Stephanie Okey sold 6,900 shares of the business's stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $35.67, for a total value of $246,123.00. Following the transaction, the director owned 6,400 shares in the company, valued at approximately $228,288. The trade was a 51.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Coelho Rogerio Vivaldi sold 3,000 shares of the company's stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $40.00, for a total value of $120,000.00. Following the transaction, the director directly owned 19,225 shares of the company's stock, valued at $769,000. The trade was a 13.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is currently owned by company insiders.

Institutional Trading of Crinetics Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRNX. Wellington Management Group LLP raised its holdings in Crinetics Pharmaceuticals by 44.3% in the 3rd quarter. Wellington Management Group LLP now owns 8,381,991 shares of the company's stock worth $349,110,000 after purchasing an additional 2,574,683 shares in the last quarter. Farallon Capital Management LLC raised its stake in Crinetics Pharmaceuticals by 20.2% during the fourth quarter. Farallon Capital Management LLC now owns 6,933,098 shares of the company's stock valued at $322,736,000 after buying an additional 1,163,000 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Crinetics Pharmaceuticals by 15.1% in the fourth quarter. Janus Henderson Group PLC now owns 4,440,691 shares of the company's stock worth $206,604,000 after acquiring an additional 581,900 shares in the last quarter. Paradigm Biocapital Advisors LP grew its stake in shares of Crinetics Pharmaceuticals by 8.8% in the third quarter. Paradigm Biocapital Advisors LP now owns 2,550,774 shares of the company's stock worth $106,240,000 after acquiring an additional 207,221 shares during the last quarter. Finally, RTW Investments LP increased its holdings in shares of Crinetics Pharmaceuticals by 54.9% during the fourth quarter. RTW Investments LP now owns 1,351,326 shares of the company's stock valued at $62,904,000 after acquiring an additional 478,939 shares in the last quarter. Hedge funds and other institutional investors own 98.51% of the company's stock.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.